Optimal Treatment Strategies for use of Anti-Obesity Medications (AOMs) in Children and Adolescents Research Coordinating Center
This grant funds a center to coordinate research on the safest and most effective use of anti-obesity medications in children and teens, supporting clinical trials and data management across multiple sites.
Funder: National Institutes of Health
Due Dates: December 1, 2026 (Estimated)
Funding Amounts: One award anticipated; ceiling and floor not specified.
Summary: Supports a Research Coordinating Center to lead, manage, and harmonize clinical research on anti-obesity medication strategies for children and adolescents.
Key Information: This is a forecasted opportunity; all dates are estimated and subject to change.
Description
This funding opportunity invites applications to establish a Research Coordinating Center (RCC) for a consortium of clinical centers focused on optimizing anti-obesity medication (AOM) treatment strategies in children and adolescents. The consortium will design and implement studies to maximize the benefits and minimize the risks of AOM use in youth. Key research priorities include:
- Determining the optimal developmental stage for AOM initiation
- Assessing the rate and amount of weight loss, medication class, dose, frequency, and duration
- Evaluating the content and intensity of adjunct lifestyle therapies to support healthy psychological and physical development and potentially avoid lifelong AOM dependence
- Identifying predictors of response or nonresponse to various treatment strategies
The RCC will be responsible for providing leadership and expertise in statistical design and analysis, coordinating research activities (including data collection with a central laboratory), harmonizing data collection methods, managing data and biospecimens, and fostering collaborations across the consortium.
